These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 21507982)

  • 1. Molecular mechanisms of viral and host cell substrate recognition by hepatitis C virus NS3/4A protease.
    Romano KP; Laine JM; Deveau LM; Cao H; Massi F; Schiffer CA
    J Virol; 2011 Jul; 85(13):6106-16. PubMed ID: 21507982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Control of innate immune signaling and membrane targeting by the Hepatitis C virus NS3/4A protease are governed by the NS3 helix α0.
    Horner SM; Park HS; Gale M
    J Virol; 2012 Mar; 86(6):3112-20. PubMed ID: 22238314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extended interaction networks with HCV protease NS3-4A substrates explain the lack of adaptive capability against protease inhibitors.
    Dultz G; Shimakami T; Schneider M; Murai K; Yamane D; Marion A; Zeitler TM; Stross C; Grimm C; Richter RM; Bäumer K; Yi M; Biondi RM; Zeuzem S; Tampé R; Antes I; Lange CM; Welsch C
    J Biol Chem; 2020 Oct; 295(40):13862-13874. PubMed ID: 32747444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonstructural protein 3-4A: the Swiss army knife of hepatitis C virus.
    Morikawa K; Lange CM; Gouttenoire J; Meylan E; Brass V; Penin F; Moradpour D
    J Viral Hepat; 2011 May; 18(5):305-15. PubMed ID: 21470343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A macrocyclic HCV NS3/4A protease inhibitor interacts with protease and helicase residues in the complex with its full-length target.
    Schiering N; D'Arcy A; Villard F; Simic O; Kamke M; Monnet G; Hassiepen U; Svergun DI; Pulfer R; Eder J; Raman P; Bodendorf U
    Proc Natl Acad Sci U S A; 2011 Dec; 108(52):21052-6. PubMed ID: 22160684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular determinants of TRIF proteolysis mediated by the hepatitis C virus NS3/4A protease.
    Ferreon JC; Ferreon AC; Li K; Lemon SM
    J Biol Chem; 2005 May; 280(21):20483-92. PubMed ID: 15767257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Understanding the structural and energetic basis of inhibitor and substrate bound to the full-length NS3/4A: insights from molecular dynamics simulation, binding free energy calculation and network analysis.
    Xue W; Wang M; Jin X; Liu H; Yao X
    Mol Biosyst; 2012 Oct; 8(10):2753-65. PubMed ID: 22833015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepacivirus NS3/4A Proteases Interfere with MAVS Signaling in both Their Cognate Animal Hosts and Humans: Implications for Zoonotic Transmission.
    Anggakusuma ; Brown RJP; Banda DH; Todt D; Vieyres G; Steinmann E; Pietschmann T
    J Virol; 2016 Dec; 90(23):10670-10681. PubMed ID: 27654291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis C virus variants resistant to macrocyclic NS3-4A inhibitors subvert IFN-β induction by efficient MAVS cleavage.
    Welsch C; Haselow K; Gouttenoire J; Schneider M; Morikawa K; Martinez Y; Susser S; Sarrazin C; Zeuzem S; Antes I; Moradpour D; Lange CM
    J Hepatol; 2015 Apr; 62(4):779-84. PubMed ID: 25463536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis C virus protease NS3/4A cleaves mitochondrial antiviral signaling protein off the mitochondria to evade innate immunity.
    Li XD; Sun L; Seth RB; Pineda G; Chen ZJ
    Proc Natl Acad Sci U S A; 2005 Dec; 102(49):17717-22. PubMed ID: 16301520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative proteomics identifies the membrane-associated peroxidase GPx8 as a cellular substrate of the hepatitis C virus NS3-4A protease.
    Morikawa K; Gouttenoire J; Hernandez C; Dao Thi VL; Tran HT; Lange CM; Dill MT; Heim MH; Donzé O; Penin F; Quadroni M; Moradpour D
    Hepatology; 2014 Feb; 59(2):423-33. PubMed ID: 23929719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enzymatic characterization of membrane-associated hepatitis C virus NS3-4A heterocomplex serine protease activity expressed in human cells.
    Hamill P; Jean F
    Biochemistry; 2005 May; 44(17):6586-96. PubMed ID: 15850392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis C virus NS3/4A protease inhibits complement activation by cleaving complement component 4.
    Mawatari S; Uto H; Ido A; Nakashima K; Suzuki T; Kanmura S; Kumagai K; Oda K; Tabu K; Tamai T; Moriuchi A; Oketani M; Shimada Y; Sudoh M; Shoji I; Tsubouchi H
    PLoS One; 2013; 8(12):e82094. PubMed ID: 24349192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New details of HCV NS3/4A proteinase functionality revealed by a high-throughput cleavage assay.
    Shiryaev SA; Thomsen ER; Cieplak P; Chudin E; Cheltsov AV; Chee MS; Kozlov IA; Strongin AY
    PLoS One; 2012; 7(4):e35759. PubMed ID: 22558217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Canine hepacivirus NS3 serine protease can cleave the human adaptor proteins MAVS and TRIF.
    Parera M; Martrus G; Franco S; Clotet B; Martinez MA
    PLoS One; 2012; 7(8):e42481. PubMed ID: 22870331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A wide range of NS3/4A protease catalytic efficiencies in HCV-infected individuals.
    Franco S; Clotet B; Martínez MA
    Virus Res; 2008 Feb; 131(2):260-70. PubMed ID: 18037183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of substrate specificity in NS3/4A serine protease by biased sequence search threading.
    Ozdemir Isik G; Ozer AN
    J Biomol Struct Dyn; 2017 Apr; 35(5):1102-1114. PubMed ID: 27122119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recruitment of an interferon molecular signaling complex to the mitochondrial membrane: disruption by hepatitis C virus NS3-4A protease.
    Hiscott J; Lacoste J; Lin R
    Biochem Pharmacol; 2006 Nov; 72(11):1477-84. PubMed ID: 16876765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Crystal structure of Dengue virus NS3 protease in complex with a Bowman-Birk inhibitor: implications for flaviviral polyprotein processing and drug design.
    Murthy HM; Judge K; DeLucas L; Padmanabhan R
    J Mol Biol; 2000 Aug; 301(4):759-67. PubMed ID: 10966782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding.
    Romano KP; Ali A; Royer WE; Schiffer CA
    Proc Natl Acad Sci U S A; 2010 Dec; 107(49):20986-91. PubMed ID: 21084633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.